A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer
TerminatedPhase 4NCT00381095
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
Brief summary (from the registry)
The purpose of this study is to assess the analgesic efficacy of flexibly-dosed pregabalin in the adjunctive treatment of subjects with cancer-induced bone pain.
Study details
- Official title
- A Randomized Placebo-Controlled Trial Of The Efficacy And Tolerability Of Flexibly Dosed Pregabalin In The Treatment Of Cancer-Induced Bone Pain
- Conditions
- Bone Neoplasms
- Pain, Intractable
- Cancer
- Interventions
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Organization
- Pfizer
- Start date
- 2006-12
- Primary completion
- 2010-10
- Sex
- All
- Age range
- from 18 Years
- Results posted
- Yes, on ClinicalTrials.gov
- Countries
- Canada, Czechia, Egypt, Finland, France, Hungary, Italy, Mexico, Peru, Philippines, Poland, Russia, South Korea, Spain, Sweden, Taiwan, Thailand, United States, Venezuela
- Total sites listed
- 55
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patient must have a malignant, solid tumor that has been diagnosed as having metastasized to bone, and must have moderate to severe pain secondary to the bone metastasis at an identifiable reference site. Exclusion Criteria: * The patient who has undergone diagnostic or therapeutic invasive interventions (angiography, biopsy, surgery) less than 15 days prior to study start that would impact their assessment of pain at the reference pain site or area, in the opinion of the investigator.
Canadian sites (1)
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00381095